Pacira BioSciences (PCRX) Stock Price, News & Analysis

-0.91 (-3.39%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
359,410 shs
Average Volume
494,406 shs
Market Capitalization
$1.20 billion
P/E Ratio
Dividend Yield
Price Target

Pacira BioSciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
91.2% Upside
$49.50 Price Target
Short Interest
8.04% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.35mentions of Pacira BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.79 M Sold Last Quarter
Proj. Earnings Growth
From $2.18 to $2.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.95 out of 5 stars

Medical Sector

11th out of 909 stocks

Pharmaceutical Preparations Industry

5th out of 423 stocks

PCRX stock logo

About Pacira BioSciences Stock (NASDAQ:PCRX)

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Stock Price History

PCRX Stock News Headlines

Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
PCRX Apr 2024 22.500 put
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Navigating 4 Analyst Ratings For Pacira BioSciences
Q4 2023 Pacira Biosciences Inc Earnings Call
Preview: Pacira BioSciences's Earnings
Pacira BioSciences Q4 2023 Earnings Preview
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$41.96 million
Pretax Margin


Sales & Book Value

Annual Sales
$674.98 million
Cash Flow
$3.99 per share
Book Value
$18.74 per share


Free Float
Market Cap
$1.22 billion
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

PCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price target for 2024?

10 Wall Street research analysts have issued 1 year target prices for Pacira BioSciences' stock. Their PCRX share price targets range from $42.00 to $57.00. On average, they predict the company's stock price to reach $49.50 in the next twelve months. This suggests a possible upside of 91.2% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2024?

Pacira BioSciences' stock was trading at $33.74 at the beginning of the year. Since then, PCRX shares have decreased by 23.3% and is now trading at $25.89.
View the best growth stocks for 2024 here

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PCRX earnings forecast

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Thursday, February, 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.71. The business had revenue of $181.24 million for the quarter, compared to analysts' expectations of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a trailing twelve-month return on equity of 12.81%.

What ETFs hold Pacira BioSciences' stock?
What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (2.24%), Tributary Capital Management LLC (0.54%), Assenagon Asset Management S.A. (0.42%), Gradient Investments LLC (0.30%), Congress Asset Management Co. MA (0.19%) and Bridge City Capital LLC (0.13%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCRX) was last updated on 4/24/2024 by Staff

From Our Partners